Shenqi fuzheng, an injection concocted from chinese medicinal herbs, combined with platinum-based chemotherapy for advanced non-small cell lung cancer: a systematic review

Dong, Ju; Su, Shi-Yue; Wang, Min-Yan; Zhan, Zhen

doi:10.1186/1756-9966-29-137

Journal of Experimental & Clinical Cancer Research

Table 2 Study characteristics and quality

From: Shenqi fuzheng, an injection concocted from chinese medicinal herbs, combined with platinum-based chemotherapy for advanced non-small cell lung cancer: a systematic review

Studies (Author)	Year	Chemotherapy regimen^a		Number (T/C)	Type of Assessable Outcomes	Jadad Scores^b
		treatment	control
Hao XL[20]	2008	NP+SFI	NP	60/68	WBC/HB/PLT/nausea and vomiting toxicity, KPS	3
Wang K[21]	2007	NP+SFI	NP	18/18	tumor response, WBC/PLT toxicity, KPS	3
Kang GY[22]	2006	NP+SFI	NP	36/36	tumor response, WBC/PLT/HB/nausea and vomiting toxicity, KPS	2
Gong ZM[23]	2008	NP+SFI	NP	33/32	tumor response, WBC/PLT/HB/nausea and vomiting toxicity, KPS	2
Wang XY[24]	2007	NP+SFI	NP	35/34	tumor response, WBC/PLT/HB/nausea and vomiting toxicity,	4
Wang YZ[25]	2007	NP+SFI	NP	28/27	tumor response, KPS, WBC/PLT/HB toxicity	3
Li TW[26]	2009	NP+SFI	NP	36/33	tumor response, the KPS	4
Li Y[27]	2007	NP+SFI	NP	44/43	tumor response, WBC/PLT/nausea and vomiting toxicity,	4
Lv J[28]	2008	NP+SFI	NP	40/40	tumor response, WBC/PLT/HB/nausea and vomiting toxicity, KPS	4
Zhao ZY[29]	2007	NP+SFI	NP	35/34	tumor response, WBC/PLT/HB nausea and vomiting toxicity,	4
Geng L[30]	2004	NP+SFI	NP	25/15	tumor response, KPS	2
Yu QZ[31]	2007	NP+SFI	NP	30/32	tumor response, KPS	4
Liu CL[32]	2004	NP+SFI	NP	60/60	tumor response, WBC/PLT/HB toxicity	2
Liu PH[33]	2007	NP+SFI	NP	30/30	tumor response, KPS	1
Pan YK[34]	2008	NP+SFI	NP	45/45	tumor response, WBC/PLT/HB toxicity	2
Zheng JH[35]	2009	NP+SFI	NP	42/42	tumor response, WBC/PLT/HB/nausea and vomiting toxicity	4
Miao SR[36]	2010	NP+SFI	NP	38/41	tumor response, the KPS, WBC/PLT/nausea and vomiting toxicity	3
Li YQ[37]	2010	NP+SFI	NP	43/42	KPS	5
Geng D[38]	2007	NP+SFI	NP	42/26	tumor response, WBC/the nausea and vomiting toxicity	2
Zou Y[39]	2005	TP+SFI	TP	24/24	tumor response, KPS	3
Luo SZ[40]	2006	TP+SFI	TP	25/25	tumor response, KPS, WBC/PLT/nausea and vomiting toxicity	2
Luo SW[41]	2007	TP+SFI	TP	30/30	tumor response, WBC/PLT/HB/nausea and vomiting toxicity, KPS	2
Zhang FL[42]	2008	TP+SFI	TP	30/30	tumor response, WBC/PLT/HB/nausea and vomiting toxicity, KPS	3
Zhao YX[43]	2009	TP+SFI	TP	40/40	tumor response, KPS	2
Yu F[44]	2007	DC+SFI	DC	30/30	tumor response, WBC/PLT/HB toxicity	4
He WJ[45]	2008	GP+SFI	GP	35/35	tumor response, WBC/PLT/HB/nausea and vomiting toxicity, KPS	3
Liang K[46]	2010	GP+SFI	GP	39/37	tumor response, KPS,	2
Chen J[47]	2007	TP/NP+SFI	TP/NP	41/39	tumor response, KPS	2
Wu L[48]	2004	TP/NP+SFI	TP/NP	30/30	tumor response, WBC toxicity	5

Abbreviations: SFI, shenqi fuzheng injection; NP, vinorelbine, cisplatin; TP, paclitaxel, carboplatin; DC, docetaxel cisplatin; GP, gemcitabine cisplatin;T/C, treatment group/control group; KPS, Karnofsky Performance status; WBC, white blood cell; PLT, platelet; HB, hemoglobin;
a: all patients included in studies in both groups received systemic chemotherapy therapy, and no patients received surgery and radiation, The only difference between the two groups was whether they received SFI.
b: modified Jadad scale was used.

Back to article page

ISSN: 1756-9966

Contact us

Submission enquiries: Access here and click Contact Us
General enquiries: info@biomedcentral.com